← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
California Northstate University
Elk Grove, CA
$3,363,131
Total funding
6
Grants
Funding over time
peak $1.1M · FY2016–22$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$3,363,131 · 6
By mechanism
R01$2,690,498 · 4
R15$421,195 · 1
R21$251,438 · 1
Investigators at California Northstate University
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Gestational Hyperandrogenism in Cardiovascular Programming$743,522
R01 · FY2020 · HL
Gestational Hyperandrogenism in Cardiovascular Programming$703,339
R01 · FY2021 · HL
Targeting GPR109A for the treatment of pain in systemic lupus erythematosus$435,185
R01 · FY2022 · NS
Role of the AR-ErbB3-Nrdp1 axis in mediating prostate cancer health disparities$421,195
R15 · FY2016 · CA
Recapitulation of sex- disparity in PAH on a microfluidic device and elucidation of the differences and similarities in the development, progression and therapy of PAH in male versus female patients$365,632
R01 · FY2021 · HL
Recapitulation of sex- disparity in PAH on a microfluidic device and elucidation of the differences and similarities in the development, progression and therapy of PAH in male versus female patients$361,652
R01 · FY2022 · HL
Identification of Synthetic Lethal Partners of Cancer Germline Mutations using PanCancer Human Primary Tumor Data$182,700
R21 · FY2019 · CA
Identification of Synthetic Lethal Partners of Cancer Germline Mutations using PanCancer Human Primary Tumor Data$68,738
R21 · FY2020 · CA
Targetable and Inhalable Nanoparticle Based Combination Therapy for PAH$45,677
R01 · FY2018 · HL
Gestational Hyperandrogenism in Cardiovascular Programming$35,491
R01 · FY2022 · HL